Published Online
on May 25, 2006

A more recent version of this article appeared on July 1, 2006

This Article Full Text (PDF) All Versions of this Article: 37/7/1725    most recent 01.STR.0000226642.55207.94v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Andersohn, F. Articles by Garbe, E. Search for Related Content PubMed PubMed Citation Articles by Andersohn, F. Articles by Garbe, E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CELECOXIB Related Collections Risk Factors Acute Cerebral Infarction Epidemiology

Submitted on January 25, 2006
Revised on March 19, 2006
Accepted on April 6, 2006

Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs and the Risk of Ischemic Stroke. A Nested Case-Control Study

Frank Andersohn MD; René Schade MD; Samy Suissa PhD; and Edeltraut Garbe MD, PhD^*

From the Department of Clinical Pharmacology (F.A., R.S., E.G.), Charité - Universitaetsmedizin Berlin, Berlin, Germany; and McGill Pharmacoepidemiology Research Unit (S.S.), Division of Clinical Epidemiology, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada.

^* To whom correspondence should be addressed. E-mail: edeltraut.garbe{at}charite.de.

Background and Purpose--Several randomized trials and a large number of epidemiological studies have provided evidence of an increased risk of acute myocardial infarction associated with the use of cyclooxygenase (COX)-2 selective nonsteroidal anti-inflammatory drugs (NSAIDs). Few data are available concerning the risk of ischemic stroke associated with COX-2 inhibitors.

Methods--We performed a nested case-control study in a cohort of 469 674 patients registered within the UK General Practice Research Database (GPRD), who had at least 1 prescription of an NSAID between June 1, 2000 and October 31, 2004. A total of 3094 cases with ischemic stroke were identified and 11 859 controls were matched on age, sex, year of cohort entry and general practice. Odds ratios (ORs) of ischemic stroke associated with the use of COX-2 selective NSAIDs were calculated by conditional logistic regression.

Results--Current use of rofecoxib (OR=1.71; 95% CI, 1.33 to 2.18), etoricoxib (OR=2.38; 95% CI, 1.10 to 5.13), but not of celecoxib (OR=1.07; 95% CI, 0.79 to 1.44) was associated with a significantly increased risk of ischemic stroke. For rofecoxib and etoricoxib, ORs tended to increase with higher daily dose and longer duration of use and were also elevated in patients without major stroke risk factors.

Conclusions--Our study suggests that COX-2 selective NSAIDs differ in their potential to cause ischemic cerebrovascular events. An increased risk of ischemic stroke may be influenced by additional pharmacological properties of individual COX-2 inhibitors.

Key words: epidemiology • cyclooxygenase 2 inhibitors • risk factors • stroke

This article has been cited by other articles:

				N. Latimer, J. Lord, R. L Grant, R. O'Mahony, J. Dickson, P. G Conaghan, and on behalf of the National Institute for Health and Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis BMJ, July 14, 2009; 339(jul14_1): b2538 - b2538. [Abstract] [Full Text] [PDF]

				I. J Douglas and L. Smeeth Exposure to antipsychotics and risk of stroke: self controlled case series study BMJ, August 28, 2008; 337(aug28_2): a1227 - a1227. [Abstract] [Full Text] [PDF]

				C. L. Roumie, E. F. Mitchel Jr, L. Kaltenbach, P. G. Arbogast, P. Gideon, and M. R. Griffin Nonaspirin NSAIDs, Cyclooxygenase 2 Inhibitors, and the Risk for Stroke Stroke, July 1, 2008; 39(7): 2037 - 2045. [Abstract] [Full Text] [PDF]

				M. D. M. Haag, M. J. Bos, A. Hofman, P. J. Koudstaal, M. M. B. Breteler, and B. H. C. Stricker Cyclooxygenase Selectivity of Nonsteroidal Anti-inflammatory Drugs and Risk of Stroke Arch Intern Med, June 9, 2008; 168(11): 1219 - 1224. [Abstract] [Full Text] [PDF]

				F. Kamachi, H. S. Ban, N. Hirasawa, and K. Ohuchi Inhibition of Lipopolysaccharide-Induced Prostaglandin E2 Production and Inflammation by the Na+/H+ Exchanger Inhibitors J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 345 - 352. [Abstract] [Full Text] [PDF]

				F. Andersohn, S. Suissa, E. Garbe, S. Solomon, J. Wittes, N. Arber, M. Bertagnolli, E. Hawk, B. Levin, the APC and PreSAP Trial Investigators, et al. Risks and Benefits of Celecoxib to Prevent Colorectal Adenomas N. Engl. J. Med., November 30, 2006; 355(22): 2371 - 2373. [Full Text] [PDF]